LaMeditech Signs Two Exclusive Distribution Deals With the UK and Ireland

[Financial News] LaMeditech has signed two product-specific exclusive distribution agreements for the UK and Irish markets.
LaMeditech, a company specializing in laser medical and beauty devices, said on the 13th that it had signed separate exclusive distribution agreements for its professional skincare device, PuraCell MX, and personal-use beauty device, PuraCell Miin, at Cosmoprof Asia 2026, held from the 11th to the 13th at the Hong Kong Convention and Exhibition Centre (HKCEC).
PuraCell MX was contracted to a local distributor specializing in beauty devices, while PuraCell Miin was contracted to a distributor specializing in home beauty products. The parties used demo units for several months and reviewed the products’ performance and market potential before signing the agreements.
The agreements give LaMeditech distribution networks in the UK and Ireland spanning both its professional and personal-use product lines. The local distributor for PuraCell Miin is also discussing product supply with a major UK cosmetics brand.
The exhibition also featured the Rainjet laser medical device and Lifcell, a professional skincare treatment device. Rainjet uses a 2,940-nm erbium:YAG (Er) laser and applies microchanneling technology to create tiny channels in the skin. A key feature is its use of laser-assisted drug delivery technology (LADD). Lifcell is a professional device specialized in lifting treatments.
At the exhibition, LaMeditech introduced the features and use cases of the two products and discussed supply and distribution plans tailored to the characteristics of each national market. Buyers from other parts of Europe also showed interest, and some purchased demo units. The company plans to continue discussions on additional distribution agreements after the exhibition.
LaMeditech has participated in Cosmoprof Asia since 2023, expanding its network of overseas buyers. At this exhibition, it unveiled Rainjet for the first time after receiving manufacturing approval from South Korea’s Ministry of Food and Drug Safety and filing a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA).
LaMeditech CEO Choi Jong-seok said, “We plan to expand local product supply through our distribution networks in the UK and Ireland and identify additional overseas partners.”

[email protected] Jung Sang-hee Reporter